<DOC>
	<DOC>NCT00111449</DOC>
	<brief_summary>The purpose of this study is to determine the effect of etanercept 50 mg twice weekly compared to placebo over 12 weeks on the psoriasis area and severity index (PASI) in subjects with psoriasis. This study will also evaluate the safety and tolerability of etanercept 50 mg twice weekly; determine the effect of etanercept 50 mg twice weekly on patient reported outcomes (PRO); and characterize the pharmacokinetics (PK) profile of etanercept 50 mg twice weekly.</brief_summary>
	<brief_title>Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Active, but clinically stable, plaque psoriasis involving greater than or equal to 10% of the body surface area A minimum PASI score of 10 obtained during the screening period Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit Evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of an investigational product on psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Psoriasis, adults</keyword>
	<keyword>skin, Phase 3</keyword>
	<keyword>clinical trial, Amgen</keyword>
	<keyword>etanercept, EnbrelÂ®</keyword>
	<keyword>moderate, severe</keyword>
</DOC>